Anatomy & Physiology Study Guide
  1. 22.1

    Whole blood, plasma and the formed elements

    • A centrifuged tube layers into packed red cells at the bottom, a thin buffy coat of WBCs and platelets, and straw-colored plasma on top.
    • Whole blood is about 45 percent formed elements and 55 percent plasma; red cells are over 99 percent of the formed elements.
    • Hematocrit is the red cell share of total volume: about 40 to 55 percent in men and 36 to 48 percent in women (labs vary), since testosterone raises EPO.
    • Low hematocrit means anemia; high means polycythemia or a shrunken plasma volume from dehydration, and either way viscosity and flow resistance shift.

    Outcome

    1. 1Describe the components of whole blood, plasma and formed elements and calculate hematocrit and plasma fraction from a centrifuged tube.
  2. 22.1

    Working a centrifuged tube

    • Hematocrit equals the packed-cell column height divided by the full column height, times 100.
    • A 10 cm column with 4.5 cm of packed cells has a hematocrit of 45 percent; plasma is the remaining 55 percent, because the buffy coat is negligible.
    • Plasma volume equals total blood volume times (1 minus hematocrit): 5 L of blood at hematocrit 45 percent holds about 2.75 L of plasma.
    • Packing is imperfect: 3 to 4 percent of the plasma stays trapped among the red cells, so the true hematocrit is about 96 percent of the measured one.

    Outcome

    1. 1Describe the components of whole blood, plasma and formed elements and calculate hematocrit and plasma fraction from a centrifuged tube.
  3. 22.1

    Plasma proteins and oncotic pressure

    • Plasma is about 91.5 percent water; proteins are about 7 percent by weight and the liver makes most of them.
    • By share of protein: albumin 54 percent, globulins 38 percent, fibrinogen 7 percent. Gamma globulins are antibodies from plasma cells; alpha and beta globulins carry iron, lipids and vitamins.
    • Fibrinogen is factor I and becomes fibrin in clotting; serum is plasma after clotting, so it lacks fibrinogen and other consumed clotting factors.
    • Oncotic pressure is about 25 mm Hg (Guyton gives 28), roughly 80 percent from albumin: osmotic pressure follows molecule number, and albumin is small (about 69,000) and plentiful.
    • Low albumin (liver disease, nephrotic syndrome, malnutrition) lowers oncotic pressure, so filtration exceeds reabsorption and edema forms.

    Outcome

    1. 2Classify plasma proteins by origin and function, including albumin, globulins, fibrinogen and their contribution to oncotic pressure.
  4. 22.1

    Reference properties of blood

    • pH is 7.35 to 7.45, slightly alkaline; temperature is about 38 C, roughly 1 C above oral temperature.
    • Volume is about 5 L in an adult, 7 to 8 percent of body weight; the textbook rule is about 75 mL/kg in men and 65 mL/kg in women, so size and sex matter.
    • Viscosity is about 3 times that of water, set mostly by red cell number plus plasma proteins; in polycythemia vera it can reach about 10 times.
    • Plasma osmolality is about 275-295 mOsm/kg of water (older texts round to 300); ADH, aldosterone and ANP regulate water excretion to hold volume and osmolality steady.

    Outcome

    1. 3Give the reference values for blood volume, pH, viscosity and osmolality and explain what changes each.
  5. 22.1

    The hematopoietic hierarchy

    • Pluripotent stem cells make up only 0.05 to 0.1 percent of red marrow cells; they self-renew and split into myeloid and lymphoid stem cells.
    • Myeloid line gives red cells, platelets, monocytes, neutrophils, eosinophils and basophils; lymphoid line gives B, T and NK cells and finishes maturing in lymphatic tissue.
    • Committed progenitors (CFU-E, CFU-Meg, CFU-GM) cannot self-renew and look like lymphocytes; recognizable precursors (blasts) follow.
    • Erythroid precursors eject the nucleus to become reticulocytes, megakaryocytes fragment into platelets, and granulocytes and monocytes share a progenitor.

    Outcome

    1. 4Trace hematopoiesis from the hematopoietic stem cell through myeloid and lymphoid progenitors to each mature cell line.
  6. 22.1

    Where blood forms and what drives it

    • Before birth: yolk sac first, then liver from about week 7 (spleen and lymphoid organs also help). Marrow is colonized near week 11 and leads after about week 20, the main site for life.
    • Newborn marrow is all red; with age the shaft marrow turns to fatty yellow marrow, which can revert to red in severe blood loss.
    • Adult red marrow lies mainly in the axial skeleton, pectoral and pelvic girdles and the proximal humerus and femur.
    • EPO (kidney) drives red cells and thrombopoietin (liver) drives platelets; G-CSF and GM-CSF stimulate white cells, IL-5 eosinophils and IL-7 lymphoid cells.
    • Recombinant EPO treats anemia of kidney failure; CSFs and thrombopoietin speed recovery after chemotherapy and marrow transplant.

    Outcome

    1. 5Name the sites of blood cell formation across fetal life, childhood and adulthood and the cytokines that drive each lineage.
  7. 22.1

    Reading bone marrow

    • Red marrow is cellular, with islands of developing cells beside leaky sinusoids; yellow marrow is mostly adipocytes.
    • Megakaryocytes are huge multilobed cells beside sinusoids; platelets bud off into the sinusoid lumen.
    • Erythroid cells shrink as they mature, cytoplasm shifts from deep blue to pink as hemoglobin accumulates, and the nucleus condenses and is ejected.
    • Granulocyte precursors go from myeloblast to myelocyte and metamyelocyte (nucleus indents, specific granules appear) to band and segmented cell.
    • Aspirate samples cells and core biopsy shows architecture, usually from the iliac crest.

    Outcome

    1. 6Recognize bone marrow cell lineages and red versus yellow marrow on marrow smears and sections.
  8. 22.2

    Red cell shape, membrane and metabolism

    • A mature RBC is a biconcave disc about 7 to 8 micrometers across with no nucleus; the thin shape puts hemoglobin close to the membrane for fast gas diffusion.
    • Extra membrane for the volume lets the cell fold through narrow capillaries without stretching and rupturing.
    • Spectrin, ankyrin, band 3 and protein 4.1 anchor the membrane to the cytoskeleton; defects cause hereditary spherocytosis and elliptocytosis.
    • No mitochondria: glycolysis makes ATP; the pentose phosphate pathway makes NADPH, so G6PD deficiency gives oxidant hemolysis with Heinz bodies.
    • Lifespan is about 120 days; counts are about 4.6 to 6.2 million per microliter in men and 4.2 to 5.4 million in women.

    Outcome

    1. 7Describe the biconcave RBC shape, membrane cytoskeleton and anucleate metabolism and explain how they support gas transport and deformability.
  9. 22.2

    Hemoglobin and the oxygen curve

    • HbA is a tetramer of two alpha and two beta chains; each carries a heme with one Fe2+ that binds one O2.
    • Adult hemoglobin is over 95 percent HbA, 2 to 3 percent HbA2 (alpha2 delta2) and about 1 to 2 percent HbF (alpha2 gamma2).
    • Binding is cooperative: each bound O2 shifts the molecule from the tense to the relaxed state, making further binding easier and giving a sigmoid curve.
    • Right shift (easier unloading) with higher PCO2, H+, temperature and 2,3-BPG, the Bohr effect; left shift with the opposite, with CO and with HbF.
    • HbF binds 2,3-BPG less strongly, so it takes up more O2 at low PO2, favoring transfer from maternal blood across the placenta.

    Outcome

    1. 8Explain the structure of adult, fetal and variant hemoglobin, including heme, globin chains and the cooperative binding that shapes the oxyhemoglobin dissociation curve.
  10. 22.2

    Hemoglobin variants and heme synthesis

    • Sickle cell disease: Glu6Val in beta globin lets deoxygenated HbS polymerize, causing sickling, vaso-occlusion and hemolysis; trait protects against malaria.
    • Thalassemias reduce alpha or beta chain output; unpaired chains damage cells and cause microcytic anemia, and beta-thalassemia raises HbA2 and HbF.
    • Methemoglobin contains Fe3+ and cannot bind O2.
    • Heme synthesis starts with ALA synthase, which needs vitamin B6; lead inhibits ALA dehydratase and ferrochelatase.

    Outcome

    1. 8Explain the structure of adult, fetal and variant hemoglobin, including heme, globin chains and the cooperative binding that shapes the oxyhemoglobin dissociation curve.
  11. 22.2

    Erythropoietin and oxygen sensing

    • Peritubular interstitial cells of the renal cortex make EPO when O2 delivery falls; the liver is the main source in the fetus and newborn.
    • In normoxia prolyl hydroxylase marks HIF-alpha for VHL-mediated destruction; in hypoxia HIF-alpha is stabilized and raises EPO gene transcription.
    • EPO acts on CFU-E and proerythroblasts through its receptor and JAK2-STAT5, preventing apoptosis and speeding maturation.
    • Altitude and anemia raise EPO; in kidney failure EPO stays low despite anemia, so hematocrit falls and recombinant EPO corrects it.
    • Polycythemia vera has JAK2 V617F with low EPO, while EPO doping raises hematocrit and viscosity.

    Outcome

    1. 9Describe regulation of erythropoietin by renal hypoxia through HIF and predict its response to altitude, anemia and renal failure.
  12. 22.2

    Iron: absorption, transport, storage, recycling

    • Most body iron sits in hemoglobin; heme iron is absorbed better than non-heme iron, and total iron is regulated mainly by changing the rate of absorption.
    • Duodenal enterocytes reduce Fe3+ to Fe2+, take it up through DMT1 and export it through ferroportin.
    • In plasma, iron travels on transferrin; stores are ferritin (and hemosiderin) in liver, muscle and macrophages; erythroblasts take iron up by transferrin receptor endocytosis.
    • Macrophages recycle iron from aged red cells back onto transferrin.
    • Hepcidin from the liver blocks ferroportin: it rises with inflammation (anemia of chronic disease) and falls in iron deficiency and hemochromatosis.

    Outcome

    1. 10Trace dietary iron absorption, transport, storage and recycling, including hepcidin.
  13. 22.2

    Vitamin B12 and folate

    • Both are needed to make thymidylate for DNA; without them DNA replication stalls while RNA and hemoglobin synthesis continue, so precursors grow large (megaloblastic anemia).
    • B12 needs intrinsic factor from gastric parietal cells and is absorbed in the terminal ileum; loss of intrinsic factor (pernicious anemia, gastrectomy) causes deficiency.
    • Folate is absorbed in the jejunum and its stores last months; B12 stores last years.
    • A smear shows macro-ovalocytes and hypersegmented neutrophils; B12 deficiency also damages the spinal cord, and a raised methylmalonic acid separates it from folate deficiency.

    Outcome

    1. 11Explain the roles of vitamin B12 and folate in DNA synthesis and the absorption of B12 requiring intrinsic factor.
  14. 22.2

    Classifying anemia

    • First by size using MCV: microcytic under 80 fL, normocytic about 80 to 100 fL, macrocytic over 100 fL; then by mechanism: low production, high destruction, or blood loss.
    • Microcytic: iron deficiency, thalassemia, chronic disease, sideroblastic. Normocytic: acute blood loss, hemolysis, renal disease. Macrocytic: B12 or folate deficiency, liver disease, alcohol.
    • The reticulocyte count separates underproduction (low) from blood loss or hemolysis (high).
    • Iron deficiency: low ferritin, high TIBC, small pale cells. Chronic disease: high ferritin with low iron and low TIBC. Overload: high ferritin and high transferrin saturation.
    • Aplastic anemia is pancytopenia with a hypocellular marrow; renal anemia reflects low EPO.

    Outcome

    1. 12Classify anemias by MCV and mechanism and interpret hemoglobin, MCV, reticulocyte count and iron studies.
  15. 22.2

    Red cell destruction and jaundice

    • Aged, fragile red cells are removed by macrophages of spleen and liver; globin amino acids and iron are recycled.
    • Heme becomes biliverdin, then unconjugated bilirubin bound to albumin; the liver conjugates it into bile, and gut bacteria make urobilinogen.
    • Prehepatic jaundice (hemolysis): unconjugated bilirubin, LDH and reticulocytes rise and haptoglobin falls.
    • Hepatic jaundice reflects failed uptake, conjugation or cell damage; post-hepatic (obstructive) jaundice backs up conjugated bilirubin, giving dark urine and pale stools.
    • Newborn jaundice follows immature conjugation; very high unconjugated bilirubin can enter the brain (kernicterus).

    Outcome

    1. 13Trace RBC senescence and heme catabolism to unconjugated bilirubin and describe jaundice types.
  16. 22.3

    Granulocytes on a Wright-stained smear

    • Neutrophil: 10 to 12 micrometers, nucleus with 2 to 5 lobes joined by thin strands, fine pale lilac granules; a band has an unsegmented U-shaped nucleus.
    • Eosinophil: usually two lobes, with large uniform red-orange granules that do not hide the nucleus.
    • Basophil: slightly smaller (8 to 10 micrometers) with variable dark blue-purple granules that often obscure the two-lobed nucleus.
    • Separate by granule color, then lobes; females may show a drumstick (Barr body) on neutrophils; over five lobes suggests megaloblastic anemia.

    Outcome

    1. 14Identify the five leukocyte types on a Wright-stained smear using size, nuclear shape, chromatin and granule color.
  17. 22.3

    Agranulocytes on a smear

    • Small lymphocyte: 6 to 9 micrometers, dark round nucleus filling most of the cell, thin rim of sky-blue cytoplasm; larger lymphocytes (10 to 14) have more cytoplasm and include NK cells.
    • Monocyte: the largest leukocyte (12 to 20 micrometers) with an indented or horseshoe nucleus and abundant gray-blue cytoplasm.
    • Monocyte versus band: the monocyte is larger, with lacy chromatin and gray-blue cytoplasm; the band has a smooth, thick U-shaped nucleus and pale granules.
    • Reactive lymphocytes in viral illness are larger, with more abundant cytoplasm.

    Outcome

    1. 14Identify the five leukocyte types on a Wright-stained smear using size, nuclear shape, chromatin and granule color.
  18. 22.3

    Reference counts and common shifts

    • Total WBC is about 4500 to 11,000 per microliter; above that range is leukocytosis and below it is leukopenia (labs vary slightly).
    • Differential: neutrophils 50 to 70, lymphocytes 20 to 30, monocytes 2 to 8, eosinophils 2 to 4, basophils under 1 percent.
    • Absolute count equals percentage times total WBC: 60 percent neutrophils at 8000 per microliter is 4800 per microliter.
    • Neutrophilia: bacterial infection, stress, burns. Eosinophilia: allergy, parasites. Lymphocytosis: viral infection. Monocytosis: chronic infection such as tuberculosis.

    Outcome

    1. 15Give the reference differential and absolute counts for each leukocyte type and state the causes of common shifts.
  19. 22.3

    Leukocyte responses to infection and allergy

    • Neutrophils arrive first: selectins and integrins mediate emigration, chemotaxis guides them, and lysozyme, defensins and oxidants kill the microbe.
    • The respiratory burst depends on NADPH oxidase; its absence causes chronic granulomatous disease.
    • Monocytes arrive later in greater numbers, become macrophages and clear debris and microbes.
    • Eosinophils blunt allergic inflammation, clear antigen-antibody complexes and attack parasitic worms.
    • Basophils and mast cells release histamine and heparin and intensify inflammation and hypersensitivity.

    Outcome

    1. 16Describe the neutrophil, monocyte, eosinophil and basophil responses to infection and allergic disease at overview level.
  20. 22.3

    Megakaryocytes and platelets

    • Thrombopoietin, made in liver and kidney, pushes myeloid cells to megakaryoblasts and megakaryocytes, which fragment into 2000 to 3000 platelets each.
    • A platelet is a 2 to 4 micrometer anucleate fragment; count is about 150,000 to 400,000 per microliter, about one third is held in the spleen, and lifespan is 7 to 10 days.
    • Membrane glycoproteins matter: GPIb binds von Willebrand factor and GPIIb/IIIa binds fibrinogen.
    • Alpha granules hold vWF, fibrinogen and PDGF; dense granules hold ADP, ATP, serotonin and Ca2+.

    Outcome

    1. 17Trace platelet formation from megakaryocyte under thrombopoietin and describe the platelet granules and membrane features.
  21. 22.3

    Interpreting abnormal counts

    • Leukocytosis is a normal response to infection, stress, exercise and surgery; leukopenia follows radiation, shock, chemotherapy or marrow failure.
    • Left shift means more bands and immature forms, a marrow response to bacterial infection; hypersegmentation is the opposite pattern.
    • Thrombocytopenia causes petechiae and mucosal bleeding: minor bleeding after trauma at 20,000 to 50,000 per microliter, spontaneous bleeding at 20,000 or less, severe at 5000 or less.
    • Causes include ITP, TTP, DIC, heparin-induced thrombocytopenia and marrow failure; thrombocytosis raises the risk of thrombosis.
    • Neutropenia is a neutrophil count under about 1500 per microliter: mild 1000 to 1500, moderate 500 to 1000, severe under 500, when infection risk climbs and fever may be the only sign.

    Outcome

    1. 18Interpret leukocytosis, leukopenia, thrombocytopenia and thrombocytosis and the left shift.
  22. 22.4

    From injury to a stable plug

    • Vascular spasm: smooth muscle contracts in response to endothelin and pain reflexes, lasting up to about 30 minutes.
    • Adhesion: exposed collagen binds von Willebrand factor, which captures platelets through GPIb.
    • Activation: platelets change shape, release ADP and serotonin and make thromboxane A2 (COX-1, blocked by aspirin).
    • Aggregation: GPIIb/IIIa binds fibrinogen bridges between platelets; clopidogrel blocks the ADP receptor P2Y12.
    • Bernard-Soulier is GPIb deficiency and Glanzmann is GPIIb/IIIa deficiency; platelet defects give mucocutaneous bleeding, factor defects deep bleeding.

    Outcome

    1. 19Sequence vascular spasm, platelet plug formation (adhesion, activation, aggregation) and coagulation in a bleeding injury.
  23. 22.4

    The coagulation cascade

    • Extrinsic: tissue factor (III) with VIIa and Ca2+ activates X within seconds; PT measures this limb.
    • Intrinsic: contact activation of XII, then XI, then IX; IXa with VIIIa on a phospholipid surface activates X, taking minutes; aPTT measures this limb.
    • Common: Xa with Va, Ca2+ and phospholipid (prothrombinase) converts prothrombin to thrombin, which converts fibrinogen to fibrin.
    • Thrombin also activates V, VIII, XI and XIII; XIIIa cross-links fibrin to stabilize the clot.

    Outcome

    1. 20Diagram the intrinsic, extrinsic and common coagulation pathways with factors, cofactors, calcium and phospholipid surface.
  24. 22.4

    Cell-based model of coagulation

    • Initiation: tissue factor on cells outside the vessel binds VIIa and activates X, producing a small amount of thrombin.
    • Amplification: that thrombin activates platelets and cofactors V and VIII, and XI, on the platelet surface.
    • Propagation: tenase (IXa with VIIIa) and prothrombinase (Xa with Va) assemble on platelets, producing a large thrombin burst and fibrin.
    • Tissue factor is the physiologic trigger; this explains why XII deficiency does not cause bleeding while VIII or IX deficiency does.

    Outcome

    1. 21Explain the cell-based model of coagulation as initiation, amplification and propagation on cell surfaces.
  25. 22.4

    Reading PT, aPTT and related tests

    • PT adds tissue factor and Ca2+ and reflects VII, X, V, II and I; normal is about 11 to 13.5 seconds (INR 0.8 to 1.1), and the INR standardizes it across labs.
    • aPTT adds a contact activator, phospholipid and Ca2+ and reflects XII, XI, IX, VIII and the common pathway; normal is about 25 to 35 seconds, and it monitors unfractionated heparin.
    • Long aPTT with normal PT: factor VIII, IX or XI deficiency or heparin. Long PT with normal aPTT: factor VII deficiency or early warfarin.
    • A mixing study corrects a factor deficiency but not an inhibitor such as lupus anticoagulant.
    • Thrombin time tests fibrinogen conversion and is long with heparin or low fibrinogen; platelet count and fibrinogen cover the other limbs.

    Outcome

    1. 22Interpret PT/INR, aPTT, thrombin time, platelet count and fibrinogen results and predict which factors or drugs they reflect.
  26. 22.4

    Vitamin K, thrombin and fibrin

    • Vitamin K gamma-carboxylates glutamate on II, VII, IX, X and proteins C and S, which lets them bind Ca2+ and phospholipid.
    • Warfarin blocks vitamin K epoxide reductase; factor VII has the shortest half-life so PT lengthens first, and early protein C loss can cause skin necrosis.
    • Vitamin K comes from diet and gut bacteria; deficiency occurs in fat malabsorption and in newborns.
    • Thrombin makes fibrin, activates V, VIII, XI, XIII and platelets, and XIIIa cross-links the fibrin; 85 to 90 percent of thrombin is adsorbed onto forming fibrin.
    • On warfarin the INR target is usually 2.0 to 3.0, and 2.5 to 3.5 for some mechanical mitral valves; above the target raises bleeding risk and below it raises clot risk.

    Outcome

    1. 23Describe the roles of vitamin K, thrombin, factor XIII and fibrin in clot formation and the vitamin K dependent factors.
  27. 22.4

    Natural anticoagulants and fibrinolysis

    • Antithrombin neutralizes thrombin and Xa; heparin raises its effectiveness a hundredfold to a thousandfold, and low-molecular-weight heparin acts mainly on Xa.
    • Thrombomodulin-bound thrombin activates protein C, which with S inactivates Va and VIIIa; factor V Leiden resists this. TFPI blocks VIIa-TF-Xa.
    • tPA converts plasminogen on fibrin to plasmin, which digests fibrin into fragments including D-dimer.
    • PAI-1 inhibits tPA and alpha-2 antiplasmin inhibits plasmin; tranexamic acid blocks plasminogen binding.
    • Alteplase given early in thrombotic stroke helps, but hemorrhage must be excluded first.

    Outcome

    1. 24Explain the anticoagulant and fibrinolytic systems: antithrombin, protein C/S, TFPI, plasmin, tPA and PAI-1.
  28. 22.4

    Bleeding disorders and their steps

    • Hemophilia A (factor VIII, about 80 percent of cases) and B (factor IX, about 20 percent) are X-linked; they cause deep bleeding and joint hemorrhage with long aPTT, normal PT and normal platelets.
    • von Willebrand disease impairs platelet adhesion, giving mucocutaneous bleeding; it is the commonest inherited bleeding disorder.
    • DIC: widespread activation consumes platelets, fibrinogen and factors, giving long PT and aPTT, low platelets and fibrinogen, and raised D-dimer.
    • Liver disease lowers synthesis of most factors and prolongs PT; vitamin K deficiency does the same for the dependent factors.

    Outcome

    1. 25Relate hemophilia A and B, von Willebrand disease, DIC, thrombosis and anticoagulant drugs to specific steps of hemostasis.
  29. 22.4

    Thrombosis and where drugs act

    • Virchow triad (stasis, endothelial injury, hypercoagulability) drives thrombosis; a thrombus that breaks free is an embolus, so DVT can cause pulmonary embolism.
    • Aspirin blocks COX-1 and thromboxane A2; clopidogrel blocks P2Y12; abciximab blocks GPIIb/IIIa.
    • Heparin works through antithrombin; warfarin reduces vitamin K dependent factors.
    • DOACs inhibit Xa (rivaroxaban, apixaban) or thrombin (dabigatran).
    • Heparin-induced thrombocytopenia is paradoxically prothrombotic because anti-PF4/heparin antibodies activate platelets.

    Outcome

    1. 25Relate hemophilia A and B, von Willebrand disease, DIC, thrombosis and anticoagulant drugs to specific steps of hemostasis.
  30. 22.5

    ABO antigens and antibodies

    • A and B are carbohydrate antigens built on the H antigen: the A enzyme adds N-acetylgalactosamine, the B enzyme adds galactose, and the O enzyme is inactive so only H shows.
    • A and B alleles are codominant and O is recessive: AA or AO is type A, BB or BO type B, AB is AB, OO is type O.
    • Antibodies to the missing antigen appear within months of birth, driven by A- and B-like antigens in food and gut bacteria; they are mostly IgM.
    • Group O has anti-A and anti-B, A has anti-B, B has anti-A, and AB has neither.
    • The Bombay phenotype lacks the H antigen, so it types as O yet makes anti-H; that antibody hemolyzes all red cells except Bombay cells, so even group O blood is unsafe.

    Outcome

    1. 26Explain the ABO antigens, their biochemical basis in the H antigen and the naturally occurring antibodies.
  31. 22.5

    Predicting offspring phenotypes

    • AO times BO gives AB, AO, BO and OO in equal quarters, so all four groups can arise from one couple.
    • Rh D is dominant: D-positive people are DD or Dd and D-negative people are dd; two D-negative parents can only have D-negative children.
    • Dd times Dd gives three D-positive for every one D-negative child.
    • ABO and Rh assort independently, so multiply: AO Dd times BO Dd gives type O D-negative with probability 1/4 times 1/4, or 1/16.
    • In the US about 45 percent of people are group O, 40 percent A, 11 percent B and 4 to 5 percent AB; O positive (about 38 percent) is the commonest single type.

    Outcome

    1. 27Predict the possible offspring phenotypes of an ABO and Rh cross using the genotypes.
  32. 22.5

    Rh antigens versus ABO antibodies

    • The Rh system is protein antigens; D is the clinically dominant one, and Rh positive means D is present (over 80 percent of the US population).
    • No natural anti-D exists: an Rh-negative person forms it only after exposure, and the response builds over weeks to months.
    • Anti-D is IgG and crosses the placenta; natural anti-A and anti-B are mostly IgM, yet ABO mismatch (often group O mother) is a usually mild cause of newborn jaundice.
    • ABO mismatch reacts at once because antibodies pre-exist; Rh mismatch needs prior sensitization, so a first transfusion or pregnancy is usually spared.

    Outcome

    1. 28Compare the Rh system antigens with ABO antibodies by immunoglobulin class and clinical significance.
  33. 22.5

    Donor-recipient compatibility and crossmatch

    • Red cells: O goes to all, A to A and AB, B to B and AB, AB only to AB; O negative is the emergency donor and AB positive the universal red cell recipient.
    • Plasma compatibility is reversed: AB plasma has no anti-A or anti-B and goes to anyone; O plasma suits only group O recipients.
    • Type and screen: forward typing (patient cells with anti-A, anti-B, anti-D), reverse typing (patient serum against A and B cells) and an antibody screen.
    • Crossmatch mixes donor cells with recipient serum: immediate spin detects ABO incompatibility; an antiglobulin phase detects IgG antibodies. Clumping or hemolysis means incompatible.
    • Rh-negative women of child-bearing potential should receive D-negative products.

    Outcome

    1. 29Determine donor-recipient compatibility for red cells and plasma and describe the steps of the crossmatch.
  34. 22.5

    Hemolytic disease of the fetus and newborn

    • An Rh-negative mother is sensitized by D-positive fetal cells entering her blood, most often at delivery; without prophylaxis this happens in about 13 to 16 percent of such pregnancies.
    • In a later D-positive pregnancy IgG anti-D crosses the placenta and destroys fetal red cells, causing anemia, hydrops and bilirubin accumulation; kernicterus is a risk after birth.
    • Prevention: Rh immune globulin at about 28 weeks and within 72 hours after delivery of an Rh-positive baby, and after sensitizing events; a Kleihauer-Betke test or flow cytometry sizes a large bleed.
    • Immune globulin was licensed for routine postpartum use in 1968; with antenatal plus postpartum doses, sensitization falls below about 0.2 percent.

    Outcome

    1. 30Explain hemolytic disease of the fetus and newborn and the role of anti-D prophylaxis.
  35. 22.5

    Transfusion reactions and first response

    • Acute hemolytic reaction (ABO mismatch): intravascular hemolysis with fever, hypotension, flank pain, hemoglobinuria, kidney injury and possible DIC.
    • First steps: stop the transfusion, keep IV access with saline, recheck labels and patient identity, send samples to the blood bank and support blood pressure and urine output.
    • Delayed hemolytic reaction occurs days later in a sensitized patient, with extravascular hemolysis and a positive direct antiglobulin (Coombs) test.
    • Non-hemolytic: febrile (leukocyte cytokines), allergic or anaphylactic (IgA deficiency), TRALI (donor anti-leukocyte antibodies, lung injury) and TACO (volume overload).

    Outcome

    1. 31Describe the acute and delayed hemolytic and non-hemolytic transfusion reactions and the initial management.